We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Novo-Nordisk A/S (NOVO B) DKK0.2 B

Sell:741.40 DKK Buy:741.70 DKK Change: 2.90 DKK (0.39%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:741.40 DKK
Buy:741.70 DKK
Change: 2.90 DKK (0.39%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:741.40 DKK
Buy:741.70 DKK
Change: 2.90 DKK (0.39%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Contact details

Novo Alle 1
+45 (44) 448888

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.31 trillion DKK
Shares in issue:
2.27 billion
Copenhagen Stock Exchange
Danish Krone
OMX Copenhagen 20

Key personnel

  • Helge Lund
    Independent Chairman of the Board
  • Lars Fruergaard Joergensen
    President, Chief Executive Officer
  • Jeppe Christiansen
    Vice Chairman of the Board
  • Karsten Munk Knudsen
    Chief Financial Officer, Executive Vice President
  • Maziar Doustdar
    Executive Vice President, International Operations
  • Mads Krogsgaard Thomsen
    Chief Science Officer, Executive Vice President
  • Monique Carter
    Executive Vice President - People and Organisation
  • Ludovic Helfgott
    Executive Vice President of Biopharm
  • Douglas Langa
    Executive Vice President, North America Operations
  • Camilla Sylvest
    Executive Vice President, Commercial Strategy & Corporate Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.